End stage renal disease drugs market was valued at $25,200.2 million in 2025 and is projected to reach $63,126.2 million by 2035, growing at a CAGR of 9.7% during the forecast period (2026-2035). End-Stage Renal Disease (ESRD) represents the final and most severe stage of chronic kidney disease, characterized by the near-complete loss of kidney function. At this critical stage, patients require renal replacement therapy in the form of lifelong dialysis or kidney transplantation to survive. According to the United States Renal Data System (USRDS) 2024 Annual Data Report, approximately 131,000 new ESRD cases were reported in 2022, bringing the total number of individuals living with ESRD in the United States to nearly 816,000. Dialysis remains the most widely adopted treatment option, with two primary modalities available: Hemodialysis (HD) and Peritoneal Dialysis (PD). Hemodialysis can be administered either in specialized dialysis centers or at home, while peritoneal dialysis is predominantly home-based. Among these, in-center hemodialysis continues to be the most common treatment approach, typically requiring patients to undergo sessions three times per week, with each session lasting approximately three to four hours. The growing prevalence of ESRD is driving sustained demand for dialysis services and supportive pharmacological therapies, thereby fueling expansion in the ESRD drugs market.
Browse the full report description of “End Stage Renal Disease Drugs Market Size, Share & Trends Analysis Report by Product (Erythropoietin, Calcimimetics, Vitamins & Nutritional Supplements, Potassium Binders and Calcium-Based Phosphate Binders), by Route of Administration (Oral, Injectable, Topical), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/end-stage-renal-disease-drugs-market
In response to the rising burden of kidney disease, governments across the globe are actively strengthening dialysis infrastructure to enhance patient access to care. Growing patient volumes, coupled with limited access to timely treatment, have accelerated investments in public dialysis programs and public–private partnership (PPP) models. These initiatives aim to enhance treatment capacity, reduce waiting times, and improve affordability for underserved populations. For instance, in July 2025, Delhi government recently added 150 new haemodialysis machines across six government hospitals under a public-private partnership (PPP) model. Burari Hospital received the largest allocation, with 55 machines installed. This expansion builds upon earlier efforts in January, when 150 machines were operationalized across 10 hospitals—90 under the Prime Minister National Dialysis Programme (PMNDP) and 60 through the PPP framework. Through this latest addition, Delhi now operates 300 dialysis machines across 16 government hospitals, reinforcing its commitment to providing free dialysis services, reducing patient waiting times, and improving access for economically disadvantaged populations.
Market Coverage
Key questions addressed by the report.
Global End Stage Renal Disease Drugs Market Report Segment
By Type
By Route of Administration
Global End Stage Renal Disease Drugs Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/end-stage-renal-disease-drugs-market